Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma

Biomedical Imaging and Intervention Journal

Volumn 7, Issue 1, 2011, Pages

  Liu, Z ^a   Cheng, M ^a   Cao, M Z ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; Molecular imaging

Indexed keywords

BH3 PROTEIN; DEATH RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; GENE MUTATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR IMAGING; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 79954478490     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.7.1.e5     Document Type: Article

References (93)

1. Wunder A, Straub RH, Gay S, Funk J and Müller-Ladner U. Molecular imaging: novel tools in visualizing rheumatoid arthritis. Rheumatology (Oxford) 2005; 44(11): 1341-1349.
2. Jaffer FA and Weissleder R. Molecular imaging in the clinical arena. JAMA 2005; 293(7): 855-862.
3. Blasberg R. Imaging gene expression and endogenous molecular processes: molecular imaging. J Cereb Blood Flow Metab 2002; 22(10): 1157-1164.
4. Strasser A, O'Connor L and Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
5. Guicciardi ME and Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54(7): 1024-1033.
6. Kiliçarslan A, Kahraman A, Akkiz H, Yildiz Menziletoglu S, Fingas CD, Gerken G and Canbay A. Apoptosis in selected liver diseases. Turk J Gastroenterol 2009; 20(3): 171-179.
7. Igney FH and Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2(4): 277-288.
8. Seeff LB and Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25(27): 3771-3777.
9. Ikeguchi M, Hirooka Y and Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002; 95(9): 1938-1945.
10. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254(3): 439-459.
11. Fischer U and Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005; 57(2): 187-215.
12. Corazza N, Kassahn D, Jakob S, Badmann A and Brunner T. TRAIL-induced apoptosis between tumor therapy and immunopathology. Ann N Y Acad Sci 2009; 1171: 50-58.
13. Johnstone RW, Ruefli AA and Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108(2): 153-164.
14. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY and Yoo NJ. Expression of Fas and Fasrelated molecules in human hepatocellular carcinoma. Hum Pathol 2001; 32(3): 250-256.
15. Shin EC, Shin JS, Park JH, Kim JJ, Kim H and Kim SJ. Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett 1998; 134(2): 155-162.
16. Takahashi M, Saito H, Okuyama T, Miyashita T, Kosuga M, Sumisa F, Yamada M, Ebinuma H and Ishii H. Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody-mediated apoptosis. J Hepatol 1999; 31(2): 315-322.
17. Lian Z, Liu J, Pan J, Satiroglu Tufan NL, Zhu M, Arbuthnot P, Kew M, Clayton MM and Feitelson MA. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology 2001; 34(1): 146-157.
18. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y and Omata M. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology 2002; 296(1): 84-93.
19. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T and Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31(5): 1080-1085.
20. Herr I, Schemmer P and Büchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007; 46(1): 266-274.
21. Finnberg N and El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008; 7(11): 1525-1528.
22. Du J, Liang X, Liu Y, Qu Z, Gao L, Han L, Liu S, Cui M, Shi Y, Zhang Z, Yu L, Cao L, Ma C, Zhang L, Chen Y and Sun W. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ 2009; 16(2): 219-229.
23. Zender L, Hütker S, Mundt B, Waltemathe M, Klein C, Trautwein C, Malek NP, Manns MP, Kühnel F and Kubicka S. NF kappaBmediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Hepatology 2005; 41(2): 280-288.
24. Shah K, Tang Y, Breakefield X and Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22(44): 6865-6872.
25. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K and Nakano T. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 2003; 83(7): 1033-1043.
26. Li Q, Ching AK, Chan BC, Chow SK, Lim PL, Ho TC, Ip WK, Wong CK, Lam CW, Lee KK, Chan JY and Chui YL. A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway. J Biol Chem 2004; 279(50): 52106-52116.
27. Chan BC, Ching AK, To KF, Leung JC, Chen S, Li Q, Lai PB, Tang NL, Shaw PC, Chan JY, James AE, Lai KN, Lim PL, Lee KK and Chui YL. BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma. Oncogene 2008; 27(9): 1208-1217.
28. Ma S, Chen GG and Lai PBS. Bcl-2 family members in hepatocellular carcinoma (HCC)-mechanisms and therapeutic potentials. In: Chen GG, Lai PBS, eds. Apoptosis in Carcinogenesis and Chemotherapy. Hong Kong, China: Springer Netherlands, 2009; 219-235.
29. Cory S, Huang DC and Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22(53): 8590-8607.
30. Mott JL and Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007; 46(3): 906-911.
31. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M and Wacheck V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006; 44(1): 151-157.
32. Takehara T, Liu X, Fujimoto J, Friedman SL and Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001; 34(1): 55-61.
33. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S and Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135(6): 604-612.
34. Chen GG, Lai PB, Chan PK, Chak EC, Yip JH, Ho RL, Leung BC and Lau WY. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer 2001; 37(13): 1695-1702.
35. Chang YC and Xu YH. Expression of Bcl-2 inhibited Fasmediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res 2000; 10(3): 233-42.
36. D'Alessandro N, Poma P and Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol 2007; 13(14): 2037-43.
37. Shi YH, Ding WX, Zhou J, He JY, Xu Y, Gambotto AA, Rabinowich H, Fan J and Yin XM. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 2008; 48(2): 497-507.
38. Riedl SJ and Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5(11): 897-907.
39. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U and Eisenhut M. 131I-labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med 2005; 46(6): 1066-1074.
40. Zhou D, Chu W, Rothfuss J, Zeng C, Xu J, Jones L, Welch MJ, and Mach RH. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 2006; 16(19): 5041-5046.
41. Kim K, Lee M, Park H, Kim JH, Kim S, Chung H, Choi K, Kim IS, Seong BL and Kwon IC. Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. J Am Chem Soc 2006; 128(11): 3490-3491.
42. Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO and Tung CH. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004; 6(2): 95-105.
43. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N and Bogyo M. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 2009; 15(8): 967-973.
44. Guan YS, La Z, Yang L, He Q and Li P. p53 gene in treatment of hepatic carcinoma: Status quo. World J Gastroenterol 2007; 13(7): 985-992.
45. Jeng YM, Peng SY, Lin CY and Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10(6): 2065-2071.
46. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR and Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 1999; 87(5): 1973-1977.
47. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K and Nakano H. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999; 30(2): 413-421.
48. Hirohashi S. Pathology and molecular mechanisms of multistage human hepatocarcinogenesis. Princess Takamatsu Symp 1991; 22: 87-93.
49. Farazi PA, Glickman J, Horner J and Depinho RA. Cooperative interaction of p53 mutation, telomerase dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006; 66(9): 4766-4773.
50. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R and Gelovani Tjuvajev J. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001; 98(16): 9300-9305.
51. Epstein RJ and Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007; 13(1): 11-17.
52. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba II. Nuclear factor-?B (NF-?B) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006; 107(11): 2637-2646.
53. Naugler WE and Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18(1): 19-26.
54. Sen R and Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47(6): 921-928.
55. Feo F, Frau M, Tomasi ML, Brozzetti S and Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med 2009; 234(7): 726-736.
56. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15(5): 513-520.
57. Yang LQ, Fang DC, Wang RQ and Yang SM. Effect of NF-?B, survivin, Bcl-2 and caspase 3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 2004; 10(1): 22-25.
58. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG and Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258(5089): 1798-1801.
59. Bond M, Fabunmi RP, Baker AH and Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435(1): 29-34.
60. Block TM, Mehta AS, Fimmel CJ and Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22(33): 5093-5107.
61. Arsura M and Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005; 229(2): 157-169.
62. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y. NF-?B functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431(7007): 461-466.
63. Massagué J. TGF beta in cancer. Cell 2008; 134(2): 215-230.
64. Roberts RA, Michel C, Coyle B, Freathy C, Cain K and Boitier E. Regulation of apoptosis by peroxisome proliferators. Toxicol Lett 2004; 149(1-3): 37-41.
65. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, Wan D and Gu J. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 2008; 123(4): 972-978.
66. Yang YA, Zhang GM and Feigenbaum L. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 2006; 9(6): 445-457.
67. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8(1): 61-70.
68. Hunter AM, LaCasse EC and Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12(9): 1543-1568.
69. Salvesen GS and Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3(6): 401-410.
70. Ryan BM, O'Donovan N and Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35(7): 553-562.
71. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S and Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131(6): 1758-1767.
72. Zhu H, Chen XP, Zhang WG, Luo SF and Zhang BX. Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 2005; 11(25): 3855-3859.
73. Ye CP, Qiu CZ, Huang ZX, Su QC, Zhuang W, Wu RL and Li XF. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007; 13(46): 6264-6268.
74. Louie AY, Hüber MM, Ahrens ET, Rothbächer U, Moats R, Jacobs RE, Fraser SE and Meade TJ. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18(3): 321-325.
75. Hoehn M, Himmelreich U, Kruttwig K and Wiedermann D. Molecular and cellular MR imaging: potential and challenges for neurological applications. J Magn Reson Imaging 2008; 27(5): 941-954.
76. Aung W, Hasegawa S, Koshikawa-Yano M, Obata T, Ikehira H, Furukawa T, Aoki I and Saga T. Visualization of in vivo electroporation-mediated transgene expression in experimental tumors by optical and magnetic resonance imaging. Gene Ther 2009; 16(7): 830-839.
77. Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N, Bauer E, Parrish C, MacLaren DC, Borghei AR, Green LA, Sharfstein S, Berk AJ, Cherry SR, Phelps ME and Herschman HR. Imaging of adenoviral-directed herps simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 1998; 39(11): 2003-2011.
78. Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Satyamurthy N, Wu L, Green LA, Bauer E, MacLaren DC, Nguyen K, Berk AJ, Cherry SR and Herschman HR. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad U S A 1999; 96(5): 2333-2338.
79. Iyer M, Barrio JR, Namavari M, Bauer E, Satyamurthy N, Nguyen K, Toyokuni T, Phelps ME, Herschman HR and Gambhir SS. 8-[18F] Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med 2001; 42(1): 96-105.
80. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH and Ross BD. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000; 2(6): 491-495.
81. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, and Contag PR. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003; 20(8): 733-744.
82. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Darkes M, Robbins RC, Maecker HT and Strauss HW. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95(11): 6349-6354.
83. Schellenberger EA, Sosnovik D, Weissleder R and Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 2004; 15(5): 1062-1067.
84. Zhao M, Beauregard DA, Loizou L, Davletov B and Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001; 7(11): 1241-1244.
85. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA and Slegers G. Apoptosis-detecting radioligand: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31(6): 887-919.
86. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, Gibson DF and Krohn KA. Evaluation of 18F-Annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46(4): 658-666.
87. Lahorte C, Dumont F, Slegers G, Van De Wiele C, Dierckx RA and Philippé J. Synthesis and in vitro stability of 123I-labelled annexin V: a potential agent for SPECT imaging of apoptotic cells. J Labelled Cpd Radiopharm 2000; 43(7): 739-751.
88. Ito M, Tomiyoshi K and Takahashi N Development of a new ligand, 11C-labelled annexin V, for PET imaging of apoptosis [abstract]. J Nucl Med 2002; 43(5): 362P.
89. Luker GD and Luker KE. Optical imaging: current applications and future directions. J Nucl Med 2008; 49(1): 1-4.
90. Dumont EA, Reutelingsperger CP, Smits JF, Daemen MJ, Doevendans PA, Wellens HJ and Hofstra L. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 2001; 7(12): 1352-1355.
91. Yang SK, Attipoe S, Klausner AP, Tian R, Pan D, Rich TA, Turner TT, Steers WD and Lysiak JJ. In vivo detection of apoptotic cells in the testis using fluorescence labeled annexin V in a mouse model of testicular torsion. J Urol 2006; 176(2): 830-835.
92. Petrovsky A, Schellenberger E, Josephson L, Weissleder R and Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003; 63(8): 1936-1942.
93. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA and Tsien RY. Tumor imaging by means of proteolytic activation of cellpenetrating peptides. Proc Natl Acad Sci USA 2004; 101(51): 17867-17872.